New combo therapy aims to stall rare gut tumors

This study tests whether adding a targeted drug (sirolimus) to a standard hormone-blocking injection (octreotide) can better control advanced neuroendocrine tumors of the stomach, intestines, or pancreas. About 298 adults with tumors that cannot be removed by surgery will receive the combination. The goal is to slow tumor growth and improve outcomes, though ongoing treatment is needed.